As adiponectin substitutes are being actively investigated for a range of obesity related metabolic disease, our findings provide an impetus to examine the role of these agents in cerebral protection during the perioperative period for these patients. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.